Tennessee committee advances kratom ban after family testimony and split expert views

A Tennessee House Judiciary Committee sent House Bill 16-49 to the Finance, Ways and Means Committee after a heated hearing that included testimony from the mother of a man who died with kratom-related compounds in his system and scientists who sharply disagreed on whether regulation or an outright ban is appropriate.

The bill, presented by its sponsor, would prohibit sale and distribution of kratom, mitragynine, 7‑hydroxymitragynine and derivatives in Tennessee; establish criminal penalties; require expanded toxicology testing and medical-examiner checks; direct the Tennessee Department of Labor to add kratom to workplace drug rules; and designate the act "Matthew Davenport's Law," with an effective date of July 1, 2026. The committee voted to send the bill forward with 16 ayes, 2 nos and 1 present not voting.

Why it matters: Supporters said kratom poses a growing public-health threat in Tennessee, citing treatment demand, withdrawal complications and fatal overdoses involving multiple substances. Opponents, including scientists and patient advocates, argued that natural kratom leaf differs substantially from concentrated synthetic alkaloids and that focused regulation of high‑potency products would better protect public health without cutting off patients who report benefit.

Family testimony and medical evidence
Karen Davenport, a nurse practitioner, told the committee her 27‑year‑old son Matthew died two years ago and that toxicology identified multiple substances including mitragynine. "It became part of the combination of drugs that ended my son's life," she said, urging lawmakers to act so other families do not suffer similar losses.

Clinical and scientific views
Dr. Nick Conley, a physician in addiction medicine, said his clinic has seen an uptick in kratom-related treatment and described complex drug interactions mediated by the CYP 450 pathway that can produce hazardous effects when kratom is combined with other medications. "We are seeing those bits increase," he said, describing cases that required treatment for withdrawal and functional impacts.

By contrast, Dr. Jack Henningfield, a longtime addiction scientist who has studied kratom, told the committee there is a clear difference between the natural leaf and highly concentrated or chemically altered 7‑hydroxymitragynine. "There is a world of difference between kratom and 7‑hydroxy," he said, and recommended targeted regulation and standards for alkaloid levels rather than an outright ban on the plant leaf.

Patient access concerns
Dr. Heidi Sikora, a retired nurse practitioner and representative of the International Plant and Herbal Alliance, expressed condolences to the Davenport family but warned that a ban would remove a tolerated option for some patients with chronic pain who say other medications produce unacceptable side effects. "Natural kratom is the only option that she can tolerate that helps her function safely," Sikora said of a patient example.

Committee action and next steps
After approximately two hours of testimony and questioning, the committee moved the bill forward to Finance, Ways and Means for further consideration. No committee amendment that narrowed the scope of the ban was adopted in this hearing; members probed whether state-level regulatory standards (for example, limits on 7‑hydroxymitragynine content) could address the safety concerns raised.

The bill's next scheduled step is consideration in Finance, Ways and Means where additional fiscal and policy implications will be examined.